These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25595117)

  • 1. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
    Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
    Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM; Beier J; Candler H; Wittig T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
    Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
    Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial.
    Zhou Y; Wu F; Shi Z; Cao J; Tian J; Yao W; Wei L; Li F; Cai S; Shen Y; Wang Z; Zhang H; Chen Y; Fu Y; He Z; Chang C; Jiang Y; Chen S; Yang C; Yu S; Tian H; Cheng Q; Zhao Z; Ying Y; Zhou Y; Liu S; Deng Z; Huang P; Zhang Y; Luo X; Zhao H; Gui J; Lai W; Hu G; Liu C; Su L; Liu Z; Huang J; Zhao D; Zhong N; Ran P;
    Nat Commun; 2024 Sep; 15(1):8468. PubMed ID: 39349461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.
    Stav D; Raz M
    Chest; 2009 Aug; 136(2):381-386. PubMed ID: 19447919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
    Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
    Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
    Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
    Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
    Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
    Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: A randomized, placebo-controlled, small cohort, cross-over study.
    Ohbayashi H; Setoguchi Y; Fukuchi Y; Shibata K; Sakata Y; Arai T
    Pulm Pharmacol Ther; 2016 Apr; 37():73-80. PubMed ID: 26952317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
    Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
    Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
    COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
    van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
    J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee.
    Decramer M; Dekhuijzen PN; Troosters T; van Herwaarden C; Rutten-van Mölken M; van Schayck CP; Olivieri D; Lankhorst I; Ardia A
    Eur Respir J; 2001 Mar; 17(3):329-36. PubMed ID: 11405507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter.
    Zhang JQ; Zhang JQ; Fang LZ; Liu L; Fu WP; Dai LM
    Drug Des Devel Ther; 2015; 9():6379-87. PubMed ID: 26674585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
    Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
    Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exacerbations of chronic obstructive pulmonary disease.
    Wedzicha JA; Donaldson GC
    Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
    Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
    Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
    Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased hydrogen peroxide concentration in the exhaled breath condensate of stable COPD patients after nebulized N-acetylcysteine.
    Rysz J; Stolarek RA; Luczynski R; Sarniak A; Wlodarczyk A; Kasielski M; Nowak D
    Pulm Pharmacol Ther; 2007; 20(3):281-9. PubMed ID: 16753318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.